CN105287692A - Dalbergia benthami prain extractive, and preparation method and application thereof - Google Patents
Dalbergia benthami prain extractive, and preparation method and application thereof Download PDFInfo
- Publication number
- CN105287692A CN105287692A CN201510833439.7A CN201510833439A CN105287692A CN 105287692 A CN105287692 A CN 105287692A CN 201510833439 A CN201510833439 A CN 201510833439A CN 105287692 A CN105287692 A CN 105287692A
- Authority
- CN
- China
- Prior art keywords
- extract
- dalbergia
- lignum dalbergiae
- preparation
- japonica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 241000522195 Dalbergia Species 0.000 title abstract 8
- 239000000284 extract Substances 0.000 claims abstract description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000010992 reflux Methods 0.000 claims abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 244000184734 Pyrus japonica Species 0.000 abstract description 47
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000002009 allergenic effect Effects 0.000 abstract 1
- 244000138993 panchioli Species 0.000 description 57
- 241000894006 Bacteria Species 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 240000000513 Santalum album Species 0.000 description 4
- 235000008632 Santalum album Nutrition 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 229940093265 berberine Drugs 0.000 description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000010731 swelling symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种两粤黄檀提取物,是采用乙酸乙酯回流提取两粤黄檀的茎部得到的提取物。本发明公开了两粤黄檀提取物的制备方法,将两粤黄檀取其茎部粉碎得粉末,将所述粉末用乙酸乙酯于80℃下回流提取2-4次,每次2-3h,合并回流提取的滤液得提取液,去除所述提取液中的乙酸乙酯,干燥后即得两粤黄檀提取物。本发明公开了两粤黄檀提取物在制备抗炎和抗菌的药物制剂上的应用。本发明的两粤黄檀提取物在抗炎和抗菌上具有明显的效果,可以替代其他易致敏药物在抗炎抗菌上的应用,从而提供一个新途径。The invention discloses an extract of Dalbergia japonica, which is obtained by extracting the stem part of Dalbergia japonica by using ethyl acetate to reflux. The invention discloses a preparation method of the extract of Dalbergia liangyue. The stem of Dalbergia liangyue is crushed to obtain powder, and the powder is reflux extracted with ethyl acetate at 80°C for 2-4 times, each time 2-4 times. 3h, combine the filtrates extracted by reflux to obtain an extract, remove the ethyl acetate in the extract, and dry to obtain an extract of Dalbergia japonica. The invention discloses the application of the extract of Dalbergia japonica in the preparation of anti-inflammatory and antibacterial pharmaceutical preparations. The Dalbergia japonica extract of the invention has obvious anti-inflammatory and antibacterial effects, and can replace the application of other allergenic drugs in anti-inflammatory and antibacterial, thereby providing a new approach.
Description
技术领域technical field
本发明涉及一种两粤黄檀提取物及其制备方法和应用。The invention relates to an extract of Dalbergia japonica from Guangdong and its preparation method and application.
背景技术Background technique
炎症(inflammation)是指具有血管系统的活体组织,对各种致炎因子引起损伤所发生的以防御反应为主的病理过程。基本病理变化为变质、渗出和增生。Inflammation (inflammation) refers to a living tissue with a vascular system, which is a pathological process that mainly defends against damage caused by various inflammatory factors. The basic pathological changes are deterioration, exudation and hyperplasia.
许多中草药、天然药对细菌有抑制杀灭作用,其抗炎作用日益受到重视。壮药两粤黄檀DalbergiabenthamiPrain,又名:蕉藤麻,两粤檀,藤本,生于疏林和灌木丛中,分布在广西、广东、海南等地,药用部位为茎,又名藤春CaulisDalbergiabenthami,可用于通经活血,主治跌打损伤、筋骨疼痛和气滞血瘀所致月经不调等症状,在民间主要用于抗风湿及跌打损伤外用药,但对其药理活性的开发利用尚缺乏科学依据,极大地影响了两粤黄檀的开发和临床上的应用,目前尚未有关于两粤黄檀提取物在抗炎和抗菌上的应用说明。Many Chinese herbal medicines and natural medicines have the effect of inhibiting and killing bacteria, and their anti-inflammatory effects have been paid more and more attention. Zhuang medicine Dalbergiabenthami Prain, also known as: banana vine hemp, Liangyue sandalwood, vines, born in sparse forests and bushes, distributed in Guangxi, Guangdong, Hainan and other places, the medicinal part is the stem, also known as vine spring Caulis Dalbergiabenthami, which can be used to promote menstruation and activate blood circulation, mainly treats symptoms such as bruises, muscle and bone pain, and irregular menstruation caused by qi stagnation and blood stasis. The lack of scientific basis has greatly affected the development and clinical application of Dalbergia japonica, and there is no description of the application of Dalbergia japonica extract in anti-inflammatory and antibacterial.
发明内容Contents of the invention
本发明的一个目的是解决至少上述问题,并提供至少后面将说明的优点。It is an object of the present invention to solve at least the above-mentioned problems and to provide at least the advantages which will be described later.
本发明还有一个目的是提供一种两粤黄檀提取物,通过乙酸乙酯回流提取其茎部后干燥获得,本发明的两粤黄檀提取物具有明显的抗炎和抗菌作用。Another purpose of the present invention is to provide an extract of Dalbergia japonica, which is obtained by extracting its stem with ethyl acetate reflux and then drying. The extract of Dalbergia japonica of the present invention has obvious anti-inflammatory and antibacterial effects.
为了实现根据本发明的这些目的和其它优点,提供了一种两粤黄檀提取物,是采用乙酸乙酯回流提取两粤黄檀的茎部得到的提取物。In order to achieve these objects and other advantages according to the present invention, an extract of Dalbergia liangyue is provided, which is obtained by extracting the stem of Dalbergia liangyue by reflux with ethyl acetate.
一种两粤黄檀提取物的制备方法,将两粤黄檀取其茎部粉碎得粉末,将所述粉末用乙酸乙酯于80℃下回流提取2-4次,每次2-3h,合并回流提取的滤液得提取液,去除所述提取液中的乙酸乙酯,干燥后即得两粤黄檀提取物。A preparation method of the extract of Dalbergia japonica, the stems of Dalbergia japonica are crushed to obtain powder, and the powder is reflux extracted with ethyl acetate at 80°C for 2-4 times, each time for 2-3 hours, Combine the filtrates extracted under reflux to obtain an extract, remove the ethyl acetate in the extract, and dry to obtain an extract of Dalbergia japonica.
优选的是,所述的两粤黄檀提取物的制备方法,将所述粉末用乙酸乙酯回流提取3次,每次2.5h。Preferably, in the preparation method of the Dalbergia japonica extract, the powder is refluxed and extracted with ethyl acetate for 3 times, each time for 2.5 hours.
优选的是,所述的两粤黄檀提取物的制备方法,所述干燥为真空干燥,干燥温度低于5℃。Preferably, in the preparation method of the Dalbergia japonica extract, the drying is vacuum drying, and the drying temperature is lower than 5°C.
优选的是,所述的两粤黄檀提取物的制备方法,每次回流提取时,乙酸乙酯的用量为待提取物重量的5-10倍。Preferably, in the preparation method of the Dalbergia japonica extract, the amount of ethyl acetate is 5-10 times of the weight of the extract to be extracted in each reflux extraction.
一种两粤黄檀提取物的应用,所述两粤黄檀提取物在制备抗炎和抗菌的药物制剂上的应用。An application of the extract of Dalbergia japonica, the application of the extract of Dalbergia japonica in the preparation of anti-inflammatory and antibacterial pharmaceutical preparations.
优选的是,所述的两粤黄檀提取物的应用,所述药物制剂包括有效量的两粤黄檀提取物和药学上可接受的辅料组成。Preferably, for the application of the Dalbergia luteum extract, the pharmaceutical preparation comprises an effective amount of the Dalbergia luteum extract and pharmaceutically acceptable auxiliary materials.
优选的是,所述的两粤黄檀提取物的应用,所述药物制剂为油剂、软膏剂、乳膏剂、糊剂或膏药剂。Preferably, for the application of the Dalbergia japonica extract, the pharmaceutical preparation is an oil, an ointment, a cream, a paste or an ointment.
本发明至少包括以下有益效果:两粤黄檀提取物制备方法简单,获取容易,对于抗炎和抗菌具有显著作用,对应用于其他产品中增强抗炎和抗菌效果有广阔的市场情景,可代替青霉素和黄连素在药物上的应用,可适用于对青霉素或黄连素过敏的使用者,从而弥补消费者因过敏而无法使用抗炎和抗菌的部分药物提供一个新途径。The present invention at least includes the following beneficial effects: the preparation method of Dalbergia japonica is simple, easy to obtain, has significant anti-inflammatory and antibacterial effects, and has a broad market scenario for enhancing anti-inflammatory and antibacterial effects in other products, and can replace The application of penicillin and berberine in medicine can be applied to users who are allergic to penicillin or berberine, thereby providing a new way to make up for the inability of consumers to use some anti-inflammatory and antibacterial drugs due to allergies.
本发明的其它优点、目标和特征将部分通过下面的说明体现,部分还将通过对本发明的研究和实践而为本领域的技术人员所理解。Other advantages, objectives and features of the present invention will partly be embodied through the following descriptions, and partly will be understood by those skilled in the art through the study and practice of the present invention.
具体实施方式detailed description
下面结合具体实施例对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能够据以实施。The present invention will be further described in detail below in conjunction with specific embodiments, so that those skilled in the art can implement it with reference to the description.
需要说明的是,下述实施方案中所述实验方法,如无特殊说明,均为常规方法,所述试剂和材料,如无特殊说明,均可从商业途径获得。It should be noted that the experimental methods described in the following embodiments, unless otherwise specified, are conventional methods, and the reagents and materials, unless otherwise specified, can be obtained from commercial sources.
原料来源:两粤黄檀,经鉴定为豆科黄檀属植物(DalbergiabenthamiPrain)。Raw material source: Guangdong Dalbergia, identified as Dalbergia benthami Prain (Dalbergiabenthami Prain).
一种两粤黄檀提取物,是采用乙酸乙酯回流提取两粤黄檀的茎部得到的提取物。An extract of Dalbergia liangyue is obtained by extracting the stem of Dalbergia liangyue by reflux with ethyl acetate.
实施例1:Example 1:
一种两粤黄檀提取物的制备方法,将两粤黄檀取其茎部,自然晾干,粉碎得粉末,将所述粉末用乙酸乙酯于80℃下回流提取2次,每次2h,合并回流提取的滤液得提取液,去除所述提取液中的乙酸乙酯,干燥后即得两粤黄檀提取物,其中,每次提取使用的乙酸乙酯的用量为待提取物重量的5倍。A method for preparing the extract of Dalbergia japonica. The stems of Dalbergia japonica are taken, dried naturally, and pulverized to obtain powder, and the powder is reflux extracted twice with ethyl acetate at 80°C, each time for 2 hours , the filtrate that merges reflux extraction obtains extracting liquid, removes the ethyl acetate in described extracting liquid, promptly obtains two Guangdong Dalbergia extracts after drying, wherein, the consumption of the ethyl acetate that extracts each time is the weight of the extract to be extracted 5 times.
实施例2:Example 2:
一种两粤黄檀提取物的制备方法,将两粤黄檀取其茎部,自然晾干,粉碎得粉末,将所述粉末用乙酸乙酯于80℃下回流提取3次,每次2.5h,合并回流提取的滤液得提取液,去除所述提取液中的乙酸乙酯,干燥后即得两粤黄檀提取物。其中,每次提取使用的乙酸乙酯的用量为待提取物重量的8倍。A method for preparing the extract of Dalbergia japonica. The stems of Dalbergia japonica are taken, dried naturally, and pulverized to obtain powder, and the powder is reflux extracted with ethyl acetate at 80° C. for 3 times, each time 2.5 h, combining the filtrates extracted by reflux to obtain an extract, removing ethyl acetate in the extract, and drying to obtain an extract of Dalbergia japonica. Wherein, the amount of ethyl acetate used for each extraction is 8 times of the weight of the extract to be extracted.
实施例3:Example 3:
一种两粤黄檀提取物的制备方法,将两粤黄檀取其茎部,自然晾干,粉碎得粉末,将所述粉末用乙酸乙酯于80℃下回流提取4次,每次3h,合并回流提取的滤液得提取液,去除所述提取液中的乙酸乙酯,干燥后即得两粤黄檀提取物。其中,每次提取使用的乙酸乙酯的用量为待提取物重量的10倍。A method for preparing the extract of Dalbergia japonica. The stems of Dalbergia japonica are taken, dried naturally, and pulverized to obtain powder, and the powder is reflux extracted with ethyl acetate at 80°C for 4 times, each time for 3 hours , combined the filtrates extracted by reflux to obtain an extract, removed the ethyl acetate in the extract, and dried to obtain an extract of Dalbergia japonica. Wherein, the amount of ethyl acetate used for each extraction is 10 times of the weight of the extract to be extracted.
实施例4:Example 4:
将两粤黄檀茎部阴干,粉碎后称取50g,用400mL乙酸乙酯80℃下回流3次,每次3h,合并三次滤液,将滤液置旋转蒸发仪中减压蒸馏,回收溶剂,残留物低温真空干燥至干,得两粤黄檀茎部位乙酸乙酯浸膏(EAE),即本发明所述的两粤黄檀提取物,得率一般为2.0%-2.8%。Dried the stems of Dalbergia japonica in the shade, crushed and weighed 50g, refluxed 3 times with 400mL ethyl acetate at 80°C for 3 hours each time, combined the filtrate three times, put the filtrate in a rotary evaporator and distilled under reduced pressure, recovered the solvent, and left The product is vacuum-dried at low temperature to dryness to obtain the ethyl acetate extract (EAE) of the stem part of Dalbergia japonica, that is, the extract of Dalbergia japonica of the present invention, and the yield is generally 2.0%-2.8%.
实施例5:Example 5:
将实施例4的两粤黄檀提取物粉碎过200目筛,取适量油相基质、稠度调节剂和乳化剂在75℃左右加热熔融制备油相,取适量保湿剂、稳定剂和水混合后置于容器中在70-75℃加热,混匀后得水相,将油相与水相混合后,超声混匀,在50-60℃下一边加入两粤黄檀提取物,一边搅拌,冷却即得油剂、软膏剂、乳膏剂、糊剂或膏药剂等不同剂型的制剂。具体剂型以适用于的产品需要为主,其中一般每毫升液体制剂或每克膏体制剂中两粤黄檀提取物含量约在20-200mg,根据适用产品的类型不同控制两粤黄檀提取物的含量,例如面部使用,则应遵循少量多次的原则。The Dalbergia japonica extract of Example 4 was crushed through a 200-mesh sieve, and an appropriate amount of oil phase base, consistency regulator and emulsifier was heated and melted at about 75°C to prepare an oil phase, and an appropriate amount of moisturizer, stabilizer and water were mixed Put it in a container and heat it at 70-75°C, mix well to get the water phase, mix the oil phase with the water phase, mix it with ultrasonic, add the Dalbergia chinensis extract at 50-60°C while stirring, and cool down That is to obtain preparations in different dosage forms such as oil, ointment, cream, paste or ointment. The specific dosage form is mainly based on the needs of the applicable products. Generally, the content of Dalbergia Dalbergia extract per milliliter of liquid preparation or per gram of paste preparation is about 20-200mg. For example, if you use it on the face, you should follow the principle of small amount and multiple times.
其中,油相基质包括但不限于硬脂酸、石蜡、蜂蜡、高级醇等,稠度调节剂包括但不限于凡士林、液体石蜡、植物油等,乳化剂包括但不限于皂类乳化剂、聚氧乙烯醚的衍生物;保湿剂包括但不限于甘油、山梨醇、丙二醇等;稳定剂可以优先使用但不限于乙二胺四醋酸二钠。Among them, the oil phase base includes but not limited to stearic acid, paraffin, beeswax, higher alcohol, etc., the consistency regulator includes but not limited to vaseline, liquid paraffin, vegetable oil, etc., and the emulsifier includes but not limited to soap emulsifier, polyoxyethylene Ether derivatives; humectants include but not limited to glycerin, sorbitol, propylene glycol, etc.; stabilizers can be preferably used but not limited to disodium edetate.
为了进一步说明本发明的两粤黄檀提取物在抗炎和抑菌上的作用,本发明通过建立小鼠耳壳肿胀的急性炎症模型从体外首次评价两粤黄檀提取物的抗炎活性,并采用滤纸片扩散法和试管法(MIC)对两粤黄檀提取物的抗菌活性进行了研究。In order to further illustrate the anti-inflammatory and antibacterial effects of the Dalbergia japonica extract of the present invention, the present invention evaluates the anti-inflammatory activity of the Dalbergia japonica extract in vitro for the first time by establishing an acute inflammation model of mouse ear shell swelling, The antibacterial activity of Dalbergia japonica extracts was studied by filter paper diffusion method and test tube method (MIC).
1.有效提取物体外抗炎作用研究1. Research on anti-inflammatory effect of effective extract in vitro
(1)二甲苯致小鼠耳廓肿胀实验(1) Xylene-induced mouse auricle swelling experiment
标准体重昆明小鼠40只随机分为四组(空白组、两粤黄檀大剂量、两粤黄檀中剂量、两粤黄檀小剂量)。小鼠左侧耳壳前后两面均匀涂抹二甲苯致炎,0.04ml/只。造模成功后,在小鼠左耳炎症部位分别涂,小鼠右耳不做任何处理。4小时后脱臼处死动物,立即沿耳廓基线剪下双耳,用直径8mm打孔器取相同部位耳片,在万分之一分析天平上称重,按右耳片重量减左耳片重量为肿胀度,将致炎一侧耳片重量减去对照一侧耳片重量即为肿胀度,观察用药前后肿胀度变化。40 Kunming mice with standard body weight were randomly divided into four groups (blank group, large dose of Dalbergia spp., medium dose of Dalbergia spp., and small dose of Dalbergia spp.). Xylene was evenly applied to the front and rear sides of the left ear shell of the mice to induce inflammation, 0.04ml/mouse. After the successful modeling, it was applied to the inflammation site of the left ear of the mouse respectively, and the right ear of the mouse was left untreated. After 4 hours, the animals were sacrificed by dislocation, and both ears were immediately cut along the base line of the auricles, and the ear pieces of the same part were taken with a hole punch with a diameter of 8 mm, weighed on a ten-thousandth analytical balance, and the weight of the left ear piece was subtracted from the weight of the right ear piece It is the degree of swelling, which is the degree of swelling by subtracting the weight of the ear piece on the side of the inflammation caused by the weight of the ear piece on the control side, and observe the change of the degree of swelling before and after the treatment.
耳肿胀度=涂药后耳重量-涂药前耳重量Ear swelling degree = ear weight after application - ear weight before application
(2)数据处理:SPSS13.0方差齐性检验。(2) Data processing: SPSS13.0 homogeneity of variance test.
表1为涂药后4h后测得的两粤黄檀提取物对小鼠耳肿胀的影响,可以看出,随着两粤黄檀提取物剂量增加,抑肿率显著增加,说明本发明的两粤黄檀提取物的抗炎效果显著,坚持使用1日3次,抗炎效果更佳。Table 1 is the effect of the Dalbergia japonica extract measured after 4h after the application on the ear swelling of mice, as can be seen, along with the increase in dosage of the Dalbergia japonica extract, the swelling suppression rate significantly increases, indicating that The anti-inflammatory effect of Liangyue Dalbergia sandalwood extract is remarkable, and the anti-inflammatory effect will be better if you insist on using it 3 times a day.
表1两粤黄檀提取物对小鼠耳肿胀的影响Table 1 Effect of Dalbergia japonica extracts on mouse ear swelling
2.两粤黄檀提取物体外抗菌活性研究2. In vitro antibacterial activity of Dalbergia japonica extracts
(1)菌液制备:将金黄色葡萄球菌、大肠杆菌、绿脓杆菌、枯草芽孢杆菌、伤寒杆菌五种菌种分别于MH琼脂平板上分区划线,37℃培养24h;接种环分别挑取各个菌种的单个菌落接种于MH肉汤中,于37℃培养24h;用麦氏比浊法调整五种菌的浓度,最终浓度为1.5×106CFU/mol。(1) Bacterial solution preparation: five strains of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, and Bacillus typhi were respectively marked on the MH agar plate, cultured at 37°C for 24 hours; the inoculation loops were picked separately A single colony of each strain was inoculated in MH broth and cultured at 37°C for 24 hours; the concentration of the five strains was adjusted by McFarland turbidimetry, and the final concentration was 1.5×106 CFU/mol.
(2)滤纸片扩散法:取0.1ml的菌悬液用无菌涂布棒均匀涂布于平板培养基(约15mL),将灭菌后直径9mm的滤纸圆片在药液(浓度250μg/mL)中浸泡20min后取出,等距离贴于平板上,每皿放4片,每菌种做3个平皿。以无菌水为空白对照,青霉素为革兰氏阳性细菌的阳性对照,黄连素作为革兰氏阴性菌的阳性对照。两粤黄檀提取物对五种菌的抑菌效果见表2。(2) Filter paper diffusion method: Take 0.1ml of the bacterial suspension and spread it evenly on the plate culture medium (about 15mL) with a sterile coating rod, and put a filter paper disc with a diameter of 9mm after sterilization in the liquid medicine (concentration: 250μg/ mL) for 20 minutes, take it out, stick it on the flat plate at equal distances, put 4 pieces in each plate, and make 3 plates for each strain. Sterile water was used as a blank control, penicillin was used as a positive control for Gram-positive bacteria, and berberine was used as a positive control for Gram-negative bacteria. The antibacterial effects of Dalbergia japonica extracts on five species of bacteria are shown in Table 2.
表2两粤黄檀提取物对五种菌的抑菌效果Table 2 The antibacterial effect of Dalbergia japonica extracts on five kinds of bacteria
注:“----”表示未测定。Note: "----" means not determined.
由表2可知,两粤黄檀提取物对枯草芽孢杆菌有明显的抑制效果,抑菌圈大小为12mm,对金黄色葡萄球菌有明显的抑制效果,抑菌圈大小为13mm。It can be seen from Table 2 that the extract of Dalbergia japonica has obvious inhibitory effect on Bacillus subtilis, the size of the inhibition zone is 12mm, and it has obvious inhibitory effect on Staphylococcus aureus, the size of the inhibition zone is 13mm.
(3)试管法(MIC):如表3,测定采用试管二倍稀释法进行最小抑菌浓度测定,取无菌试管9支,第1管加入含药肉汤1mL作为阴性对照,药物浓度为400mg/mL,第2-8管中加入含药液的肉汤各1mL,其中药物浓度依次作二倍梯度稀释,第9管加入不含药液的肉汤作为阳性对照;然后在第1-8管各加入50ul培养8h的供试菌液,充分摇匀后,于37℃培养24h,观察结果。这里的供试菌液为金黄色葡萄球菌和枯草芽孢杆菌的菌液,其中,这两种菌的浓度均为1.5×106CFU/mol。(3) Test tube method (MIC): As shown in Table 3, the minimum inhibitory concentration was measured by the test tube double dilution method. 9 sterile test tubes were taken, and 1 mL of drug-containing broth was added to the first tube as a negative control. The drug concentration was 400mg/mL, add 1mL of each broth containing drug solution to tubes 2-8, in which the drug concentration is sequentially diluted twice, and add broth without drug solution to tube 9 as a positive control; then in tubes 1-8 Each of the 8 tubes was added with 50ul of the test bacteria solution cultured for 8h, shaken well, cultured at 37°C for 24h, and observed the results. The test bacteria solution here is the bacteria solution of Staphylococcus aureus and Bacillus subtilis, wherein the concentration of these two bacteria is 1.5×106 CFU/mol.
表3最小抑菌浓度测定试验Table 3 Minimum Inhibitory Concentration Determination Test
针对上述实验,本发明的申请人得出两粤黄檀提取物对枯草芽孢杆菌、金黄色葡萄球菌的最小抑菌浓度分别为100和50mg/mL。Based on the above experiments, the applicant of the present invention obtained that the minimum inhibitory concentrations of the extracts of Dalbergia japonica from Guangdong to Bacillus subtilis and Staphylococcus aureus were 100 and 50 mg/mL, respectively.
为了进一步说明本发明的两粤黄檀提取物的疗效,列举一些病例:In order to further illustrate the curative effect of the Dalbergia japonica extract of the present invention, enumerate some cases:
典型病例:Typical cases:
1)张先生,50岁,风湿性关节炎,关节红肿,走路疼痛,涂抹采用本发明的两粤黄檀提取物制备的外用乳膏(其中,每1g外用乳膏中两粤黄檀提取物的含量为50mg),1日3次,使用7天,红肿症状减弱,再坚持使用7天,走路疼痛缓解,2个月后访问,疼痛明显减轻,坚持使用本发明的外用乳膏8个月后,再回访,走路基本无异样,与常人无异,坚持使用12个月后,疼痛消失,坚持使用18个月后再回访,病情并无反复。1) Mr. Zhang, 50 years old, rheumatoid arthritis, red and swollen joints, pain in walking, smeared the external cream that adopts the Dalbergia japonica extract of the present invention to prepare (wherein, the extract of Dalbergia japonica in every 1g cream for external use The content is 50mg), 3 times on the 1st, use 7 days, redness and swelling symptom weakens, continue to use again 7 days, walking pain relief, visit after 2 months, pain obviously alleviates, insists on using external cream of the present invention for 8 months Afterwards, a follow-up visit showed that there was basically no difference in walking, and it was no different from ordinary people. After 12 months of persistent use, the pain disappeared. After 18 months of continuous use, the patient returned to visit and the condition did not repeat.
2)简女士,30岁,使用某化妆品致面部过敏,泛红、发炎、起斑疹,使用本发明的两粤黄檀提取物制备的油剂涂抹(其中,每1mL油剂中两粤黄檀提取物的含量为20mg),每日3次,使用3天后过敏症状缓和,明显减轻,继续使用4天后,斑疹消失,炎症退去。2) Ms. Jian, 30 years old, used certain cosmetics to cause facial allergies, redness, inflammation, and macules, and used the oil preparation prepared from the extract of Dalbergia japonica of the present invention (wherein every 1mL of oil preparation contained two yellow sandalwood The content of sandalwood extract is 20mg), 3 times a day, and after 3 days of use, the allergic symptoms are relieved and obviously alleviated. After continuing to use for 4 days, the macule disappears and the inflammation subsides.
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的实施例。Although the embodiment of the present invention has been disclosed as above, it is not limited to the use listed in the specification and implementation, it can be applied to various fields suitable for the present invention, and it can be easily understood by those skilled in the art Therefore, the invention is not limited to the specific details and embodiments shown and described herein without departing from the general concept defined by the claims and their equivalents.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510833439.7A CN105287692A (en) | 2015-11-25 | 2015-11-25 | Dalbergia benthami prain extractive, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510833439.7A CN105287692A (en) | 2015-11-25 | 2015-11-25 | Dalbergia benthami prain extractive, and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105287692A true CN105287692A (en) | 2016-02-03 |
Family
ID=55185979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510833439.7A Pending CN105287692A (en) | 2015-11-25 | 2015-11-25 | Dalbergia benthami prain extractive, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105287692A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107033115A (en) * | 2017-03-14 | 2017-08-11 | 广西中医药大学 | Lignum Dalbergiae benthamii ketone and its extracting method |
CN107439426A (en) * | 2017-08-23 | 2017-12-08 | 何亮 | A kind of cultural method of loach |
CN107466920A (en) * | 2017-08-23 | 2017-12-15 | 何亮 | A kind of cultural method of ecological loach |
KR101847479B1 (en) * | 2017-06-14 | 2018-04-12 | 한국한의학연구원 | Composition for prevention or treatment of trychophytia comprising Dalbergia odorifera extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104341430A (en) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 3-phenylcoumarin robustic acid as well as extraction method and application thereof |
-
2015
- 2015-11-25 CN CN201510833439.7A patent/CN105287692A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104341430A (en) * | 2014-09-30 | 2015-02-11 | 广西中医药大学 | 3-phenylcoumarin robustic acid as well as extraction method and application thereof |
Non-Patent Citations (4)
Title |
---|
"五四"学制教材总编委会: "《生物》", 30 April 1996 * |
李全林等: "《新医药开发与研究》", 31 December 2008 * |
陈功锡等: "《湘西药用植物资源开发与可持续利用》", 31 May 2015 * |
霍丽妮等: "两粤黄檀体外抗氧化及α-葡萄糖苷酶抑制活性研究", 《江苏农业科学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107033115A (en) * | 2017-03-14 | 2017-08-11 | 广西中医药大学 | Lignum Dalbergiae benthamii ketone and its extracting method |
CN107033115B (en) * | 2017-03-14 | 2019-02-15 | 广西中医药大学 | Liangyue Dalbergia ketone and its extraction method |
KR101847479B1 (en) * | 2017-06-14 | 2018-04-12 | 한국한의학연구원 | Composition for prevention or treatment of trychophytia comprising Dalbergia odorifera extract |
CN107439426A (en) * | 2017-08-23 | 2017-12-08 | 何亮 | A kind of cultural method of loach |
CN107466920A (en) * | 2017-08-23 | 2017-12-15 | 何亮 | A kind of cultural method of ecological loach |
CN107466920B (en) * | 2017-08-23 | 2021-01-15 | 何亮 | Ecological loach breeding method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017101790A1 (en) | Pharmaceutical composition for treating cutaneous pruritus and use thereof | |
CN105287692A (en) | Dalbergia benthami prain extractive, and preparation method and application thereof | |
CN101112418B (en) | Medicinal composition for partial use for treating acne and method for preparing the same | |
CN102716395B (en) | Chinese medicine spray for skin diseases | |
CN103130865A (en) | Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof | |
CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
CN109288889A (en) | A kind of antibacterial gynecological composition, gel and preparation method thereof | |
WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
CN102716394A (en) | Medicine composition for treating skin diseases | |
CN113398237B (en) | A kind of traditional Chinese medicine composition for antibacterial, antipruritic and antidandruff and preparation method thereof | |
CN108785384A (en) | A kind of Chinese medicine composition containing zinc and its preparation for treating acne | |
CN105395593A (en) | Itching relieving ointment containing folium artemisiae argyi extract and preparation method thereof | |
CN104606615A (en) | Traditional Chinese medicine eyedrop for treating ocular inflammation and preparation method thereof | |
CN103157071B (en) | Chinese herbal compound film for treating dermatomycosis and preparation method thereof | |
CN103432049B (en) | Composition with deodorization function | |
CN106983741B (en) | Application of cyanoacrylate compounds in the preparation of medicines for treating fungal infectious diseases in humans and animals | |
JP2008506718A (en) | Pharmaceutical composition derived from Carapauguianensis | |
CN108785374A (en) | Faint scent cassia bark skin bacteriostatic gel and preparation method thereof | |
CN105326954B (en) | A kind of Chinese medicine composition and preparation method thereof for treating blear-eye | |
CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
CN108619486B (en) | Ointment for treating skin diseases and preparation method thereof | |
CN105311328A (en) | Traditional Chinese medicine composition for treating gynecological inflammation and application thereof | |
CN104586973B (en) | Preparation having antibacterial, anti-inflammatory and analgesic functions and preparation method of preparation | |
CN110882332A (en) | Traditional Chinese medicine composition for nose as well as preparation method and application thereof | |
CN104069179B (en) | A kind of antibacterial skin pharmaceutical composition and its production and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |